- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne Barmettler Discusses Potential Adverse Events Associated With Teprotumumab
Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center, outlines adverse events patients taking teprotumumab for thyroid eye disease may experience.
Women who are pregnant absolutely should not be on teprotumumab, said Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center.
Transcript
Has research been conducted on adverse events associated with teprotumumab since it has become available on the market?
Yes. Actually, even in the original studies, there were some additional side effects that patients should be aware of, and physicians. Some patients may experience hearing changes; this is often described as feeling like the patient is underwater. Some patients even feel that they lose hearing. And although some of that is reversible—that is, when the patient stops taking the medication, their hearing comes back—sometimes it is not reversible.
Another big thing to think about is that in patients with preexisting diabetes or other issues with higher blood glucose, this can cause the blood glucose to elevate dramatically. This has to be monitored carefully, because that can cause issues requiring even hospitalization.
One final thing is that teprotumumab is an insulin growth factor receptor antibody. This is really crucial in development. So women who are pregnant absolutely cannot be on this medication, as this would be very damaging. That's certainly something to think about as a lot of women who have thyroid eye disease are of childbearing age.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
